skip navigation

Skip Nav

AIDSinfo Drug Database

AIDSinfo Drug Database

Drugs by class

FDA-approved

Investigational

Valproic Acid  Audio icon

Other Names: Depakene, Depakote, Depakote ER, Epival, VPA, divalproex sodium, valproate
Drug Class: Histone Deacetylase Inhibitors
Molecular Formula: CH16 O2
Registry Number: 99-66-1 (CAS)
Chemical Name: 2-propylpentanoic acid
Chemical Class: Other Carboxylic Acid Derivatives
Company: AbbVie Inc.; Abbott Laboratories
Phase of Development: Phase II
Chemical Image:
Click image to enlarge
valproic acid
valproic acid
Molecular Weight: 144.2124

(Compound details obtained from ChemIDplus Advanced1 and NIAID Therapeutics Database2)

What is an investigational drug?

An investigational drug is one that is under study and is not approved by the U.S. Food and Drug Administration (FDA) for sale in the United States. Medical research studies are conducted to evaluate the safety and effectiveness of an investigational drug. These research studies are also called clinical trials. Once an investigational drug has been proven safe and effective in clinical trials, FDA may approve the drug for sale in the United States.

What is valproic acid?

Valproic acid is a drug that has been approved by FDA for the treatment of certain symptoms of bipolar disorder (a type of mental illness), the treatment of seizures, and the prevention of migraine headaches.3 It has been studied to see if it could be effective as part of a strategy to cure HIV infection.4,5

Currently, there is no cure for HIV infection. One of the main obstacles to curing HIV infection is that the virus can remain hidden and inactive (latent) inside certain cells of the immune system (such as resting CD4 T cells) for many months or even years. While HIV is in this latent state, the immune system cannot recognize the virus, and antiretroviral therapy (ART) has no effect on it. (ART is the recommended treatment for HIV infection and involves using a combination of different antiretroviral [ARV] drugs to prevent HIV from replicating.)6-8

Valproic acid belongs to a class (group) of HIV drugs called histone deacetylase (HDAC) inhibitors.2 HDAC inhibitors reactivate (turn back on) latent HIV within resting CD4 T cells.8,9

How do histone deacetylase (HDAC) inhibitors work?

HDAC inhibitors reactivate (turn back on) latent HIV within resting CD4 T cells. When latent HIV is reactivated, it is once again able to produce new virus and multiply (replicate). It is hoped that after latent HIV is reactivated, the CD4 T cells in which the virus was hiding are more likely to die off on their own or be recognized and killed by the body’s immune system.8,9

In addition, any new virus that is produced during reactivation can then be prevented from infecting other cells with the use of ongoing ART.8,9 Recent research has shown that additional therapies, together with HDAC inhibitors, may be needed to fully eliminate latent HIV from the body.9

How are clinical trials of investigational drugs conducted?

Clinical trials are conducted in phases. Each phase has a different purpose and helps researchers answer different questions.10

  • Phase I trials: Researchers test an investigational drug in a small group of people (20–80) for the first time. The purpose is to evaluate its safety and identify side effects.
  • Phase II trials: The investigational drug is administered to a larger group of people (100–300) to determine its effectiveness and to further evaluate its safety.
  • Phase III trials: The investigational drug is administered to large groups of people (1,000–3,000) to confirm its effectiveness, monitor side effects, compare it with standard or equivalent treatments, and collect information that will allow the investigational drug to be used safely.10

In most cases, an investigational drug must be proven safe and effective in a Phase III clinical trial to be considered for approval by FDA for sale in the United States. Some drugs go through FDA’s accelerated approval process and are approved before a Phase III clinical trial is complete. After a drug is approved by FDA and made available to the public, researchers track its safety in Phase IV trials to seek more information about the drug’s risks, benefits, and optimal use.10

In what phase of testing is valproic acid?

The use of valproic acid to reduce latent HIV has been studied in Phase II clinical trials.2

What are some studies on valproic acid?

Study Name: NCT00289952; CTN-205
Phase: II
Location: Canada (British Columbia, Ontario, and Quebec)
Participants: HIV-infected adults who were on antiretroviral therapy (ART) and who had a viral load (the amount of HIV in the blood) that was suppressed to less than 50 copies/mL for at least 1 year before starting the study. Participants had a CD4 count of at least 200 cells/mm3. (A CD4 count is a laboratory test that measures the number of CD4 cells in a sample of blood and is an important indicator of immune function. The CD4 count of a healthy person ranges from 500 to 1,600 cells/mm3.)
Purpose: The purpose of this study was to determine whether valproic acid in combination with ART could reduce the amount of latent HIV in resting CD4 T cells.
Study Design: Fifty-six HIV-infected participants were assigned to one of the following two groups:

  • Group 1: Twice-daily valproic acid plus ART for 16 weeks, followed by ART alone for 32 weeks
  • Group 2: ART alone for 16 weeks, followed by twice-daily valproic acid plus ART for 32 weeks

Results:

  • In this study, adding valproic acid to ART did not reduce the amount of latent HIV in HIV-infected participants.
  • Investigators noted that strategies using a combination of therapies, including HDAC inhibitors stronger than valproic acid, may be needed to eliminate HIV.
  • In terms of safety, study drop-outs caused by a side effect were common during valproic acid treatment.4,11,12 


Study Name: NCT00614458
Phase: II
Location: United States (North Carolina)
Participants: HIV-infected adults who were on ART and who had a suppressed viral load of less than 50 copies/mL for at least 6 months before starting the study. Participants had a CD4 count of at least 300 cells/mm3.
Purpose: The purpose of this study was to determine whether adding valproic acid and the HIV medicine raltegravir to participants’ current ART regimen could reduce the amount of latent HIV in participants’ resting CD4 T cells.
Study Design: Six participants received raltegravir twice daily plus valproic acid twice daily, in addition to their current ART regimen.
Results:

  • In this study, adding valproic acid and raltegravir to ART did not reduce the amount of latent HIV in the participants.
  • The study investigators suggested that other approaches, such as stronger HDAC inhibitors combined with intensified ART, might be needed to eliminate latent HIV infection.5,13

What side effects might valproic acid cause?

During the study that looked at adding valproic acid to ART (NCT00289952), some participants dropped out of the study because of side effects they experienced when they were receiving valproic acid. As treatment time on valproic acid increased, the number of participants dropping out of the study also increased.12

During the study that looked at adding valproic acid and raltegravir to ART (NCT0064458), no significant side effects related to valproic acid were reported.13 

Information on possible side effects of the drug is not complete. If testing of valproic acid continues, additional information on possible side effects will be gathered.

Where can I get more information about clinical trials studying valproic acid?

More information about valproic acid-related research studies is available from the AIDSinfo database of ClinicalTrials.gov study summaries. Click on the title of any trial in the list to see the ClinicalTrials.gov trial summary and more information about the study.

I am interested in participating in a clinical trial of valproic acid. How can I find more information about participating in a clinical trial?

Participating in a clinical trial can provide benefits. For example, a volunteer participant can benefit from new research treatments before they are widely available. Participants also receive regular and careful medical attention from a research team that includes doctors and other health professionals. However, clinical trials may also involve risks of varying degrees, such as unpleasant, serious, or even life-threatening side effects from the treatment being studied.10

Your health care provider can help you decide whether participating in a clinical trial is right for you. For more information, visit NIH Clinical Research Trials and You.

 

References

  1. United States National Library of Medicine. ChemIDplus Advanced. Available at: http://chem.sis.nlm.nih.gov/chemidplus/rn/99-66-1. Last accessed on July 31, 2015.
  2. National Institute of Allergy and Infectious Diseases (NIAID). NIAID ChemDB, HIV Drugs in Development. Available at: http://chemdb.niaid.nih.gov/DrugDevelopmentHIV.aspx. Last accessed on July 31, 2015.
  3. AbbVie Inc. Depakote ER: Full Prescribing Information, March 2015. DailyMed. Available at: http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0dc024ce-efc8-4690-7cb5-639c728fccac. Last accessed on July 31, 2015.
  4. McGill University Health Center. Use of Valproic Acid to Purge HIV From Resting CD4+ Memory Cells/ A Proof-of-Concept Study. In: ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). Registered on February 8, 2006. NLM Identifier: NCT00289952. Available at: https://www.clinicaltrials.gov/ct2/show/NCT00289952. Last accessed on July 31, 2015.
  5. University of North Carolina, Chapel Hill. 10493 - MK-0518 Intensification and HDAC Inhibition in Depletion of Resting CD4+ T Cell HIV Infection. In: ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). Registered on January 31, 2008. NLM Identifier: NCT00614458. Available at: https://www.clinicaltrials.gov/ct2/show/NCT00614458. Last accessed on July 31, 2015.
  6. National Institute of Allergy and Infectious Diseases (NIAID): Bulletin, dated June 16, 2009. NIAID Invites Applications to Conduct Basic Research on HIV Persistence: Studies Key to Search for a Cure. Available at: http://www.niaid.nih.gov/news/newsreleases/Archive/2009/Pages/HIV_persistence.aspx. Last accessed on July 31, 2015.
  7. National Institute of Allergy and Infectious Diseases (NIAID). HIV Hides From the Immune System. Available at: http://www.niaid.nih.gov/topics/HIVAIDS/Understanding/Biology/pages/hidesimmunesystem.aspx. Last accessed on April 30, 2014.
  8. Siliciano RF, Greene WC. HIV Latency. Cold Spring Harb Perspect Med. 2011 Sep;1(1):a007096. Available at: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3234450/. Last accessed on July 31, 2015.
  9. Rasmussen TA, Tolstrup M, Winckelmann A, Østergaard L, Søgaard OS. Eliminating the latent HIV reservoir by reactivation strategies. Hum Vaccin Immunother. 2013 Apr 1;9(4):790-799. Available at: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3903897/. Last accessed on July 31, 2015.
  10. National Institutes of Health (NIH). NIH Clinical Research Trials and You. Available at: http://nih.gov/health/clinicaltrials/index.htm. Last accessed on July 31, 2015.
  11. Routy JP, Tremblay CL, Angel JB, et al. Valproic acid in association with highly active antiretroviral therapy for reducing systemic HIV-1 reservoirs: results from a multicentre randomized clinical study. HIV Med. 2012 May;13(5):291-6. Available at: http://onlinelibrary.wiley.com/doi/10.1111/j.1468-1293.2011.00975.x/full. Last accessed on July 31, 2015.
  12. Routy JP, Angel JB, Spaans JN, et al. Design and Implementation of a Randomized Crossover Study of Valproic Acid and Antiretroviral Therapy to Reduce the HIV Reservoir. HIV Clin Trials. 2012 Nov-Dec;13(6):301-7. Available at: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3815453/. Last accessed on July 31, 2015.
  13. Archin NM, Cheema M, Parker D, et al. Antiretroviral Intensification and Valproic Acid Lack Sustained Effect on Residual HIV-1 Viremia or Resting CD4+ Cell Infection. PLoS One. 2010 Feb 23;5(2):e9390. Available at: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2826423/. Last accessed on July 31, 2015.


Last Reviewed: July 31, 2015

Back to Top